BioSpace News Archive

Stryker (NYSE:SYK) reported operating results for the third quarter of 2023.

DBV Technologies, a clinical-stage biopharmaceutical company, announced that new data on the use of Viaskin™ Peanut 250 μg in peanut-allergic toddlers will be presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, which is being held Thursday, November 9 – Monday, November 13, 2023, in Anaheim, CA.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to two new employees to purchase an aggregate of 85,000 shares of the Company’s common stock, effective as of November 1, 2023.

Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, after the market closes.

Rakuten Medical, Inc. announced that the Company will present at the 14th Annual Jefferies London Healthcare Conference being held in London, UK, on November 14-16, 2023.

Ascentage Pharma announced that results from three clinical studies of lisaftoclax, a key candidate drug in the Company’s pipeline, have been selected for presentations at the 65th American Society of Hematology Annual Meeting, marking the second consecutive year in which clinical results of lisaftoclax were selected.

Karyopharm Therapeutics Inc. today announced that several abstracts that include selinexor data in myelofibrosis (MF) have been selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 9-12, 2023, in San Diego, CA.

Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting.

Medeor Therapeutics announced positive interim data from its multicenter, international Phase III clinical trial.

Onconova Therapeutics, Inc. announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition, taking place in San Diego, California from December 9 to 12, 2023.